Aim To
review the effi cacy and
safety data on
incretin-based
therapies currently available (
exenatide,
liraglutide,
sitagliptin,
vildagliptin) for the
treatment of
type 2 diabetes mellitus in
Asian population.
Methods We conducted
Medline search of all relevant randomized clinical trials of
incretin-based
therapies for
type 2 diabetes mellitus in
Asian populations. Data pertinent to the effi cacy and
safety of
GLP-1 mimetics and
DPP-4 inhibitors were extracted and used. Results We found 14 randomized controlled trials of
incretin based-
therapy which included 3567
type 2 diabetes mellitus in
Asian population (
Japanese,
Chinese, Korean, Indian). It was shown that
incretin-based
therapies improved HbA1c at higher extent (up to -1.42% in
exenatide 10 mcg bid, -1.85% for
liraglutide 0.9 mg qd, -1.4% for
sitagliptin 100 mg and -1.4% for
vildagliptin 50 mg bid) compared to the effects observed in studies with Caucasian
population, with comparable
safety profi le. Conclusion The effi cacy of
incretin-based
therapies in
Asian patients improved glycemic
parameters in a higher
magnitude on some glycemic
parameters compared with those in Caucasian
population. These results indicate that
incretin-based
therapies may be more effective in
Asian population than in Caucasian.